# Convergence Check 88

Timestamp: 2026-05-28 07:51 CEST

## Trigger

Completion of critique-mandated lipid-metabolite-flux sensitivity tests.

## What Changed

Wave135 improved the operationalization over Wave130. Instead of asking whether
fixed IL1B/LAMP3 or lipid-loader signatures replicate, it tested candidate
genes and mechanistic lipid-flux modules directly in GSE235357 and GSE250453.

## Agreement

- There is a reproducible small-n peripheral signal in leukotriene/oxylipin
  features (`oxylipin_resolution_axis`, `leukotriene_axis`, `LTA4H`, `ALOX5`).
- The GPR183 ligand-axis score does not replicate across the two MS treatment
  datasets.
- Wave136 agrees with earlier class audits: leukotriene/oxylipin biology is not
  currently a promotable therapeutic route.

## Disagreement / Weakness

- Wave135 sees a biological signal that Wave131 class forcing did not promote.
  This is not a contradiction: Wave135 is a PBMC response sensitivity test,
  while Wave131/Wave136 apply target-nomination gates.
- The signal could mark treatment pharmacodynamics or responder immune state
  rather than a causal lipid-lysosomal controller.

## Decision

Continue. Do not promote leukotriene/oxylipin as a target. The next forcing
question is whether GPR183 can be fairly closed after separating missing spatial
evidence from negative ligand-axis/treatment-response evidence.
